Immune restoration after treatment of HIV-1 infection with highly active antiretroviral therapy (HAART)

AIDS Reviews

Volumn 4, Issue 3, 2002, Pages 157-164

  Valdez, Hernan ^a  

^a CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Antiretroviral therapy; CD4+ lymphocytes; Immune restoration; Immunization; Lymphocyte function

Indexed keywords

ANTIRETROVIRUS AGENT; CD4 ANTIGEN; CYCLOSPORIN A; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; GROWTH HORMONE; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; INTERLEUKIN 2; INTERLEUKIN 7; VIRUS RNA;

CANCER; CLINICAL TRIAL; DRUG EFFECT; FOLLOW UP; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE DEFICIENCY; IMMUNE RESPONSE; IMMUNIZATION; INFECTION; LYMPHOCYTE COUNT; LYMPHOCYTE FUNCTION; MORBIDITY; MORTALITY; NONHUMAN; REVIEW; T LYMPHOCYTE; VIRUS INHIBITION; VIRUS REPLICATION;

ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4 LYMPHOCYTE COUNT; HIV INFECTIONS; HIV-1; HUMANS; IMMUNIZATION; LYMPHOCYTE ACTIVATION; T-LYMPHOCYTES; TREATMENT OUTCOME;

EID: 0036629967     PISSN: 11396121     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (72)

1. Birx D, Brundage J, Larson K et al. The prognostic utility of delayed-type hypersensitivity skin testing in the evaluation of HIV-infected patients. Military Medical Consortium for Applied Retroviral Research. J Acquir Immune Defic Syndr 1993;6:1248-57.
2. Gottlieb M, Schroff R, Schanker H, et al. Pneumocystis carinii pneumonia and mucosal candidiasis in previously healthy homosexual men: evidence of a new acquired cellular immunodeficiency. N Engl J Med 1981;305;1425-31.
3. Mildvan D, Mathur U, Enlow R, et al. Opportunistic infections and immune deficiency in homosexual men. Ann Intern Med 1982;96:700-4.
4. Dolan M, Clerici M, Blatt S, et al. In vitro T cell function, delayed-type hypersensitivity skin testing, and CD4+ T cell subset phenotyping independently predict survival time in patients infected with human immunodeficiency virus. J Infect Dis 1995;172:79-87.
5. Cameron D, Heath-Chiozzi M, Danner S, et al. Randomised placebo-controlled trial of ritonavir in advanced HIV-1 disease. The Advanced HIV Disease Ritonavir Study Group. Lancet 1998;351:543-9.
6. Hammer S, Squires K, Hughes M, et al. A controlled trial of two nucleoside analogues plus indinavir in persons with HIV infection and CD4 cell counts of 200 per cubic millimeter or less. AIDS Clinical Trial Group 320 Study Team. N Engl J Med 1997;337:725-33.
7. Palella F Jr, Delaney K, Moorman A, et al. Declining morbidity and mortality among patients with advanced HIV infection. HIV Outpatient Study Investigators. N Engl J Med 1998;338:853-60.
8. Valdez H, Chowdhry R, Asaad R, et al. Changing spectrum of mortality due to HIV: analysis of 260 deaths during 1995-1999. Clin Infect Dis 2001;32:1487-93.
9. Yeni P, Hammer S, Carpenter C, et al. Antiretroviral treatment for adult HIV infection in 2002: updated recommendations of the International AIDS Society-USA Panel. JAMA 2002;288:222-35.
10. Tarwater P, Margolick J, Jin J, et al. Increase and plateau of CD4 T-cell counts in the 3(1/2) years after initiation of potent antiretroviral therapy. J Acquir Immune Defic Syndr 2001;27:168-75.
11. Valdez H, Smith K, Lederman M, et al. Limited immune restoration after 3 years' suppression of HIV-1 replication in patients with moderately advanced disease. AIDS 2002 (in press).
12. Valdez H, Smith K, Landay A, et al. Response to immunization with recall and neoantigens after prolonged administration of an HIV-1 protease inhibitor-containing regimen. ACTG 375 team. AIDS Clinical Trials Group. AIDS 2000;14:11-21.
13. Storek J, Gooley T, Witherspoon R, Sullivan K, Storb R. Infectious morbidity in long-term survivors of allogeneic marrow transplantation is associated with low CD4 T cell counts. Am J Hematol 1997;54:131-8.
14. Socie G, Stone J, Wingard J, et al. Long-term survival and late deaths after allogeneic bone marrow transplantation. Late Effects Working Committee of the International Bone Marrow Transplant Registry. N Engl J Med 1999;341:14-21.
15. Connick E, Lederman M, Kotzin B, et al. Immune reconstitution in the first year of potent antiretroviral therapy and its relationship to virologic response. J Infect Dis 2000;181:358-63.
16. Notermans D, Pakker N, Hamman D, et al. Immune reconstitution after 2 years of successful potent antiretroviral therapy in previously untreated HIV type 1-infected adults. J Infect Dis 1999;180:1050-6.
17. Lederman M, Connick E, Landay A, et al. Immunologic responses associated with 12 weeks of combination antiretroviral therapy consisting of zidovudine, lamivudine, and ritonavir: results of AIDS Clinical Trials Group Protocol 315. J Infect Dis 1998;178:70-9.
18. Andersson J, Fehniger T, Patterson B, et al. Early reduction of immune activation in lymphoid tissue following highly active HIV therapy. AIDS 1998;12:123-9.
19. Bucy R, Hockett R, Derdeyn C, et al. Initial increase in blood CD4(+) lymphocytes after HIV antiretroviral therapy reflects redistribution from lymphoid tissues. J Clin Invest 1999;103:1391-8.
20. Badley A, Dockrell D, Algeciras A, et al. In vivo analysis of Fas/FasL interactions in HIV-infected patients. J Clin Invest 1998;102:79-87.
21. Li T, Tubiana R, Katlama C, Calvez V, Ait Mohand H, Autran B. Long-lasting recovery in CD4 T-cell function and viral-load reduction after highly active antiretroviral therapy in advanced HIV-1 disease. Lancet 1998;351:1682-6.
22. Angel J, Parato K, Kumar A, et al. Progressive HIV-specific immune recovery with prolonged viral suppression. J Infect Dis 2001;183:546-54.
23. Kaufmann G, Bloch M, Zaunders J, Smith D, Cooper D. Long-term immunological response in HIV-1-infected subjects receiving potent antiretroviral therapy. AIDS 2000;14:959-69.
24. Autran B, Carcelain G, Li T, et al. Positive effects of combined antiretroviral therapy on CD4+ T cell homeostasis and function in advanced HIV disease (see comments). Science 1997;227:112-6.
25. Renaud M, Katlama C, Mallet A, et al. Determinants of paradoxical CD4 cell reconstitution after protease inhibitor-containing antiretroviral regimen (in process citation). AIDS 1999;13:669-76.
26. Hunt PS, Rodríguez B, Valdez H, et al. Continued CD4+ T-cell count gains in patients with 4 years of suppressed viral load on HAART. 9th CROI. Seattle 2002 [abstract].
27. Zhang L, Lewin S, Markowitz M, et al. Measuring recent thymic emigrants in blood of normal and HIV-1-infected individuals before and after effective therapy. J Exp Med 1999;190:725-32.
28. Douek D, McFarland R, Keiser P, et al. Changes in thymic function with age and during the treatment of HIV infection (see comments). Nature 1998;396:690-5.
29. Hengel R, Jones B, Kennedy M, Hubbard M, McDougal J. CD4+ T cells programmed to traffic to lymph nodes account for increases in numbers of cd4+ T cells up to 1 year after the initiation of highly active antiretroviral therapy for HIV type 1 infection. J Infect Dis 2001;184:93-7.
30. Carcelain G, Blanc C, Leibowitch J, et al. T cell changes after combined nucleoside analogue therapy in HIV primary infection. AIDS 1999;13:1077-81.
31. Bisset L, Cone R, Huber W, et al. Highly active antiretroviral therapy during early HIV infection reverses T-cell activation and maturation abnormalities. Swiss HIV Cohort Study. AIDS 1998;12:2115-23.
32. Bart P, Rizzardi G, Tambussi , et al. Immunological and virological responses in HIV-1-infected adults at early stage of established infection treated with highly active antiretroviral therapy. AIDS 2000:14:1887-97.
33. Kaufman G, Zaunders J, Cunningham P, et al. Rapid restoration of CD4 T cell subsets in subjects receiving antiretroviral therapy during primary HIV-1 infection. AIDS 200;14:2643-51.
34. Plana M, García F, Gallart T, et al. Immunological benefits of antiretroviral therapy in very early stages of asymptomatic chronic HIV-1 infection. AIDS 2001;14:1921-1933.
35. Lange H, Medvik K, Asaad R, Wild M, Kalayjian R, Lederman M. Earlier initiation of HAART better preserves immune competence even in persons who achieve "normal" CD4+ T-cell counts. XIV International AIDS Conference. Barcelona 2002 [abstract].
36. Pilcher C, Miller W, Beatty Z, Eron J. Detectable HIV-1 RNA at levels below quantifiable limits by amplicor HIV-1 monitor is associated with virologic relapse on antiretroviral therapy. AIDS 1999:13:1337-42.
37. Dornadula G, Nunnari G, Vanella M, et al. Human immunodeficiency virus type 1-infected persons with residual disease and virus reservoirs on suppressive highly active antiretroviral therapy can be stratified into relevant virologic and immunologic subgroups. J Infect Dis 2001;183:1682-7.
38. Sharkey M, Teo I, Greenough T, et al. Persistence of episomal HIV-1 infection intermediates in patients on highly active antiretroviral therapy. Nat Med 2000;6:76-81.
39. Schooley R, Mladenovic J, Sevin A, et al. Reduced mobilization of CD34+ stem cells in advanced human immunodeficiency virus type 1 disease. J Infect Dis 2000; 181: 148-57.
40. Isgro A, Mezzaroma I, Aiuti A, et al. Recovery of hematopoietic activity in bone marrow from HIV type 1-infected patients during highly active antiretroviral therapy. AIDS Res Hum Retroviruses 2000;16:1471-9.
41. Huang S, Barbour J, Deeks S, et al. Reversal of HIV type 1-associated hematosuppression by effective antiretroviral therapy. Clin Infect Dis 2000;30:504-10.
42. Jacobson M, Spritzler J, Valdez H, et al. The effects of GM-CSF on plasma HIV-1 RNA and CD4 lymphocyte counts in HIV-1 infected subjects receiving concomitant potent antiretroviral therapy. 9th CROI. Seattle 2002 [abstract].
43. Steinmann G, Klaus B, Muller-Hermelink H. The involution of the ageing human thymic epithelium is independent of puberty. A morphometric study. Scand J Immunol 1985;22:563-75.
44. Haynes B, Hale L. The human thymus. A chimeric organ comprised of central and peripheral lymphoid components. Immunol Res 1998;18:175-92.
45. Smith K, Valdez H, Landay A, et al. Thymic size and lymphocyte restoration in patients with HIV infection after 48 weeks of zidovudine, lamivudine, and ritonavir therapy. J Infect Dis 2001;181:141-7.
46. Mackall C, Fleisher T, et al. Age, thymopoiesis, and CD4+ T-lymphocyte regeneration after intensive chemotherapy. N Engl J Med 1995;332:143-9.
47. Teixeira L, Valdez H, McCune J, et al. Poor CD4 T cell restoration after suppression of HIV-1 replication may reflect lower thymic function. AIDS 2001:15:1749-56.
48. Binz K, Joller P, Froesch P, Binz H, Zapt J, Froesch E. Repopulation of the atrophied thymus in diabetic rats by insulin-like growth factor I. Proc Natl Acad Sci USA 1990;87:3690-4.
49. Napolitano L, Lo J, Gotway M, et al. Increased thymic mass and circulating naïve CD4 T cells in HIV-1-infected adults treated with growth hormone. AIDS 2002;16:1103-11.
50. Fry T, Mackall C. Interleukin-7: from bench to clinic. Blood 2002;99:3892-904.
51. Molossi S, Clausell N, Sett S, Rabinovitch M. ICAM-1 and VCAM-1 expression in accelerated cardiac allograft arteriopathy and myocardial rejection are influenced differently by cyclosporine A and tumour necrosis factor-alpha blockade. J Pathol 1995;176:175-82.
52. Petzelbauer P, Wolff K. Effects of cyclosporin A on resident and passenger immune cells of normal human skin and UV-induced erythema reactions. Br J Dermatol 1992;127:560-5.
53. Rizzardi G, Harari A, Capiluppi B, et al. Treatment of primary HIV-1 infection with cyclosporin A coupled with highly active antiretroviral therapy. J Clin Invest 2002;109:681-8.
54. Kovacs J, Vogel S, Metcalf J, et al. Interleukin-2 induced immune effects in HIV-infected patients receiving intermittent interleukin-2 immunotherapy. Eur J Immunol 2001;31:1351-60.
55. Kovacs J, Baseler M, Dewar R, et al. Increases in CD4 T lymphocytes with intermittent courses of interleukin-2 in patients with HIV infection. A preliminary study. N Engl J Med 1995;332:567-75.
56. Kovacs J, Vogel S, Albert J, et al. Controlled trial of interleukin-2 infusions in patients infected with the HIV. N Engl J Med 1996;335:1350-6.
57. 3: ACTG 328 Final Results at 84 weeks. 8th CROI. Chicago 2001 [abstract].
58. Valdez H, Pollard R, Sahner D, et al. Intermittent cycles of IL-2 increase CD4+ T-cell counts but do enhance antibody responses to immunization. XIV International AIDS Conference. Barcelona 2002 [abstract A5046s].
59. Loke R, Murray-Lyon I, Coleman J, Evans B, Zuckerman A. Diminished response to recombinant hepatitis B vaccine in homosexual men with HIV antibody: an indicator of poor prognosis. J Med Virol 1990;31:109-11.
60. Redfield B, Birx D, Ketter N, et al. A phase I evaluation of the safety and immunogenicity of vaccination with recombinant gp160 in patients with early human immunodeficiency virus infection. Military Medical Consortium for Applied Retroviral Research. N Engl J Med 1991;324:1677-84.
61. Barouch D, Santra S, Schmitz J, et al. Control of viremia and prevention of clinical AIDS in rhesus monkeys by cytokine-augmented DNA vaccination. Science 2000;290:486-92.
62. Barouch D, Kunstman J, Kuroda M, et al. Eventual AIDS vaccine failure in a rhesus monkey by viral escape from cytotoxic T lymphocytes. Nature 2002;415:335-9.
63. Jin X, Bauer D, Tuttleton S, et al. Dramatic rise in plasma viremia after CD8(+) T cell depletion in simian immunodeficiency virus-infected macaques. J Exp Med 1999;189:991-8.
64. Metzner K, Jin X, Lee F, et al. Effects of in vivo CD8(+) T cell depletion on virus replication in rhesus macaques immunized with a live, attenuated simian immunodeficiency virus vaccine. J Exp Med 2000;191:1921-31.
65. Schmitz J, Kuroda M, Santra S, et al. Control of viremia in simian immunodeficiency virus infection by CD8+ lymphocytes. Science 1999;283:857-60.
66. Ogg G, Jin X, Bonhoeffer S, et al. Decay kinetics of HIV-specific effector cytotoxic T lymphocytes after combination antiretroviral therapy. J Virol 1999; 73:797-800.
67. Rosenberg E, Billingsley J, Caliendo A, et al. Vigorous HIV-1-specific CD4+ T cell responses associated with control of viremia (see comments). Science 1997;278:1447-50.
68. Al-Harthi L, Siegel J, Spritzler J, Pottage J, Agnoli M, Landay A. Maximum suppression of HIV replication leads to the restoration of HIV-specific responses in early HIV disease. AIDS 2000;14:761-70.
69. Blankson J, Gallant J, Siliciano R. Proliferative responses to HIV-1 antigens in HIV-1-infected patients with immune reconstitution. J Infect Dis 2001;183:657-61.
70. Rosenberg E, Altfeld M, Poon S, et al. Immune control of HIV-1 after early treatment of acute infection. Nature 2000;407:523-6.
71. Betts M, Ambrozak D, Douek D, et al. Analysis of total HIV-specific CD4(+) and CD8(+) T-cell responses: relationship to viral load in untreated HIV infection. J Virol 2001;75:11983-91.
72. Altfeld M, Rosenberg E, Shankarappa R, et al. Cellular immune responses and viral diversity in individuals treated during acute and early HIV-1 infection. J Exp Med 2001;193:169-80.